Sign in

Edgar V. Lerma 🇵🇭

@edgarvlermamd.medsky.network
1.6K followers 48 following 633 posts

Chicago Sports Fan... Nephrologist by day. My tweets are not medical advice. The views expressed here are my own and not those of my employer

PostsRepliesMedia
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 4h
Clinical conditions related to LVADs that may arise during hemodialysis #Nephpearls #NephSky 👉 link.springer.com/book/10.1007...
011
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 5h
Call 📢 for papers: "The Jerry Yee: Clinical Challenges in Diagnosis and Treatment in Nephrology" #Nephpearls #NephSky 🗓️ Deadline for submissions: 15 October 2026 👉 www.sciencedirect.com/special-issu...
012
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 18h
Impact of proteinuria levels on long-term kidney outcomes in IgA nephropathy: a meta-analysis ca. 2026 from @glomcon.org Rare Kidney Disease journal #Nephpearls #NephSky 👉🏼 link.springer.com/article/10.1...
010
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 19h
Ten tips for the diagnosis and management of nephrotic syndrome ca. 2026 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42707999/
011
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 26/09/2026
Classic course of whole-kidney GFR and UAE according to the natural (proteinuric) pathway of #Diabetic #Kidney Disease (DKD) ca. 2017 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/28143897/
011
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 26/09/2026
Adults with #IgAN are at greater risk of adverse kidney outcomes versus nonglomerular CKD and substantially higher risks of heart failure and death compared with no CKD ca. 2026 from @KIReports #Nephpearls #RKDSummit #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42027552/
032
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 26/09/2026
Not all #IgAN therapies are created equal #Nephpearls #RKDSummit #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/40928891/
021
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 26/09/2026
Dipstick hemoglobinuria is associated with histologic markers of active disease in #IgAN and may provide clinically relevant information to complement current assessment of disease activity in #IgAN ca. 2026 #Nephpearls #RKDSummit #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42628835/
020
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 26/09/2026
Microscopic hematuria as a risk factor for #IgAN progression: considering this biomarker in selecting and monitoring patients ca. 2023 #Nephpearls #RKDSummit #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/38053974/
020
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 26/09/2026
Targeting B cells in immune-mediated kidney diseases: conclusions from @kdigo.org Controversies Conference ca. 2026 #Nephpearls #RKDSummit #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42034308/
041
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 25/09/2026
Colloids vs Crystalloids #Nephpearls #AKIinICU #NephSky 👉 shop.lww.com/Handbook-of-...
010
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 09/09/2026
Thank you for the kind words and the wonderful hospitality! It was an absolute honor to present at the Renal Research Forum and engage with such a fantastic group of colleagues at Mayo Clinic 🙏 #NephSky
013
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 05/09/2026
Kidney Health Guidance on Cardiovascular-Kidney-Metabolic (CKM) Syndrome ca. 2026 from @asnpublications.bsky.social #Nephpearls #NephSky #Cardiorenal 👉 pubmed.ncbi.nlm.nih.gov/42684397/
051
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 31/08/2026
Hypomagnesemia: Outpatient management #Nephpearls #NephSky 👉 shop.lww.com/Manual-of-Ne...
032
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 27/08/2026
Syndrome of Inappropriate Antidiuresis (SIAD): From Pathophysiology to Management ca. 2023 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/36974717/
042
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 25/08/2026
Lower Time Averaged-Proteinuria (TA-P) was associated with progressively reduced risk of kidney failure in adults with IgA Nephropathy #IgAN in the US ca. 2026 from @glomcon.org Rare Kidney Disease Journal #Nephpearls #NephSky 👉 link.springer.com/article/10.1...
031
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 11/08/2026
In ADPKD, probenecid reduced tolvaptan-induced polyuria and nocturia while preserving its disease-modifying effects 🔑 A potential strategy to make tolvaptan more tolerable - and a new window into renal water homeostasis #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42298327/
053
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 07/08/2026
Phase 3 proteinuria and eGFR data for available and emerging IgA Nephropathy #IgAN therapeutics (as of August 3, 2026) #Nephpearls #GlomConHawaii 🌊 #NephSky 👉 pubmed.ncbi.nlm.nih.gov/41895685/
042
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 04/08/2026
VISIONARY: Sibeprenlimab in IgA nephropathy #IgAN ✅ Proteinuria reduction ✅ Preservation of kidney function #Nephpearls #GlomConHawaii 🌊 #NephSky #VisualAbstract by @alexgr23.bsky.social
051
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 30/07/2026
nsMRAs in CKM Syndrome: Disease-Specific Deep Dives www.medscape.org/viewarticle/... via @MedscapeCME #Nephpearls #NephSky
040
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 30/07/2026
Targeting BAFF and APRIL in IgA Nephropathy reachmd.com/programs/fro... via @ReachMD #Nephpearls #NephSky
reachmd.com
Targeting BAFF and APRIL in IgA Nephropathy
Advances in our understanding of BAFF and APRIL biology are reshaping the treatment landscape for IgA nephropathy (IgAN), with dual pathway inhibition emerging as a promising disease-modifying strateg...
020
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 27/07/2026
Save the date #WCN27 🇲🇾 #ISNWCN 🇲🇾 #NephSky
021
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 19/07/2026
Urea vs. tolvaptan for hospitalized patients with SIADH ca. 2026 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42455009/
063
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 18/07/2026
Kick, Sweat, Protect: Kidney Health Through the Lens of Soccer (Football) ca. 2026 #Nephpearls #WorldCup #WorldCup2026 #NephSky 👉🏼 www.kidneymedicinejournal.org/article/S259...
032
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 16/07/2026
Enthusiasm for EGDT has waned as 3 large, multicenter trials failed to reproduce the results of the Rivers trial #Nephpearls #AKIinICU #NephSky 🔑 Current Surviving Sepsis guidelines recommend an initial bolus of 30 mL/kg to be followed by additional fluid to maintain and improve perfusion
022
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 15/07/2026
Obesity in CKD: Treatment algorithm ca. 2026 from @ndt-era.bsky.social @saynanorouzi.bsky.social @rahaai.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42446420/
082
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 15/07/2026
The kidney in the middle: @kdigo.org guidelines address multiple key components of cardiovascular-kidney-metabolic syndrome ca. 2026 from @Kidney_Int #Nephpearls #Cardiorenal #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42191113/
021
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 15/07/2026
When shock is refractory to initial fluid resuscitation, it is appropriate to consider vasopressor support #Nephpearls #AKIinICU #NephSky 📌 Distributive shock requires alpha-adrenergic stimulation to promote vasoconstriction and raise SVR
021
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 14/07/2026
Screening algorithms in septic shock #Nephpearls #AKIinICU #NephSky ⚠️ SIRS may be highly sensitive but lacks specificity ⚠️ qSOFA may lack sensitivity for early sepsis or septic shock 🔑 These limitations highlight the importance of high clinical suspicion for shock 👉 shop.lww.com/Handbook-of-...
011
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 13/07/2026
The fundamental problem in shock is "inadequate end-organ perfusion" #Nephpearls #AKIinICU #NephSky 📌 Low cardiac output (CO) ✔️ Hypovolemic ✔️ Cardiogenic ✔️ Obstructive 📌 Low systemic vascular resistance (SVR) aka Distributive: Sepsis
010
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 09/07/2026
The Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy #Nephpearls #NephSky reachmd.com/programs/med...
reachmd.com
The Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy
To understand the pathogenesis of IgA nephropathy (IgAN), it’s important to look at the immune processes driving damage caused by the disease. The 4-hit process shows why and how IgAN progresses on th...
030
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 28/06/2026
B cell maturation, treatment targets, and therapies ca. 2026 from @kidneyint.bsky.social @kdigo.org #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42034308/
050
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 23/06/2026
Fabry Disease: Current Perspectives on Diagnosis and Management Strategies ca. 2026 from @akdhjournal.bsky.social @saynanorouzi.bsky.social #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42331443/
022
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 13/06/2026
ARISE FLUIDS: Vasopressors or Fluids in Early Septic Shock ca. 2026 from @nejm.org #Nephpearls #AKIinICU #NephSky 📌 No significant difference in days alive and out of hospital at day 90 ⚠️ Pulmonary edema: Lower in restricted fluids group (0.6% vs. 5.0%) 👉 pubmed.ncbi.nlm.nih.gov/42274006/
040
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 12/06/2026
Guideline for Prevention, Detection, Evaluation, & Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome ca. 2026 from @americanheart.bsky.social @accintouch.bsky.social @amdiabetesassn.bsky.social @asnkidney.bsky.social #Nephpearls #Cardiorenal #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42265997/
041
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 12/06/2026
C3 glomerulopathy in transplant “like yet unlike native”: Pathophysiology, recent advances in therapeutics and evolving paradigms ca. 2026 @saynanorouzi.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42281853/
021
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 09/06/2026
Mechanisms by which novel antihypertensive drug classes reduce blood pressure ca. 2025 from @natrevcardiol.nature.com #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/39920248/
074
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 09/06/2026
Aprocitentan in Patients With CKD and Resistant Hypertension ca. 2026 #Nephpearls #NephSky ✅ Well tolerated ✅ Lowered BP (nighttime ambulatory BP) ✅ Markedly reduced urine albumin-to-creatinine ratio (UACR) in participants w/ CKD and resistant hypertension 👉 pubmed.ncbi.nlm.nih.gov/41363010/
062
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 07/06/2026
Hemodynamic monitoring in in ICU: Capillary refill time (CRT), is quick, easily performed, and a long-standing component of the physical exam #Nephpearls #AKIinICU #NephSky 👉 pubmed.ncbi.nlm.nih.gov/30772908/ 👉 www.wolterskluwer.com/en/solutions...
040
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 05/06/2026
FIND-CKD: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months ca. 2026 from @nejm.org #Nephpearls #ERA26 #NephSky 👉 www.nejm.org/doi/full/10....
084
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 05/06/2026
Hyperkalemia and Its Treatment: Real-World Evidence and Managed Care Considerations Supporting Use of Potassium Binders ca. 2026 from @beaverspharmd.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42213908/
031
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 05/06/2026
Consensus Recommendation: Real World Insights on Attitudes and Treatment of Hyperkalemia ca. 2026 from @garysinger.bsky.social @renalphysicians.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42069178/
191
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 05/06/2026
Treatment of chronic hyponatremia from Dr Ewout Hoorn #Nephpearls #ERA26 #NephSky
031
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 04/06/2026
Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial ca. 2026 from @asnpublications.bsky.social #Nephpearls #ERA26 #NephSky 👉 pubmed.ncbi.nlm.nih.gov/40913594/
020
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 04/06/2026
Ultrafiltration and Sodium Removal in Steady Concentration Peritoneal Dialysis: A Prospective, Multicenter, Randomized, Crossover Study ca. 2026 from @asnpublications.bsky.social @wilkiemart.bsky.social #Nephpearls #ERA26 #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42240452/
030
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 29/05/2026
C3 glomerulopathy in transplant “like yet unlike native”: Pathophysiology, recent advances in therapeutics and evolving paradigms ca. 2026 @saynanorouzi.bsky.social #Nephpearls #NephSky 👉 www.wjgnet.com/2220-3230/fu...
041
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 23/05/2026
SAVE THE DATE for upcoming #ECNeph "Nephrotic syndrome in a patient with diabetes" 🗓️ 28th May, Thursday ⏰ 8PM IST 🇮🇳, 1030AM EST 🇺🇸, 1030PM PHT 🇵🇭 #Nephpearls #NerphSky
020
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 22/05/2026
Glomerular frontiers: consensus perspectives from @glomcon.org @n0r0zha.bsky.social @poyanmehr.org @bettercallseeth.bsky.social @saynanorouzi.bsky.social #GlomconHawaii 🌊 2025 #NephSky #Nephpearls 👉 link.springer.com/article/10.1...
043
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 20/05/2026
Inpatient Hypertension ? #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/38804130/ 🔳 Was the BP measured properly and accurately? 🔳 Is there evidence of acute end-organ damage? 🔳 What potential factors are contributing to the elevated BP?
042
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 20/05/2026
Kidney disease (CKD) and heart failure (HFrEF, HFpEF): recent advances and current challenges: conclusions from @kdigo.org Controversies Conference ca. 2026 #Nephpearls #Cardiorenal #NephSky 👉 pubmed.ncbi.nlm.nih.gov/41791738/
043